Xianwei Bu - Academia.edu (original) (raw)

Papers by Xianwei Bu

$Research paper thumbnail of P185 Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis refractory to biologic therapies: 2-year results from the phase 3 SELECT-PsA 2 study$

P185 Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis refractory to biologic therapies: 2-year results from the phase 3 SELECT-PsA 2 study

Rheumatology, Apr 1, 2023

The Lancet, 2019

26 февраля 2021 года Ярославль Участники: • Насонов Евгений Львович-академик РАН, д. м.н., профес... more 26 февраля 2021 года Ярославль Участники: • Насонов Евгений Львович-академик РАН, д. м.н., профессор, Заслуженный деятель науки РФ, президент Общероссийской общественной организации «Ассоциация ревматологов России», главный внештатный специалист-ревматолог Минздрава России. • Мазуров Вадим Иванович-академик РАН, д. м.н., профессор, Заслуженный деятель науки РФ, Первый вице-президент Общероссийской общественной организации «Ассоциация ревматологов России», главный специалист-ревматолог Северо-Западного федерального округа и г. Санкт-Петербурга, директор НИИ ревматологии ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава России. • Лила Александр Михайлович-д. м.н., профессор, директор ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой». • Дубинина Татьяна Васильевна-к. м.н., и. о. генерального секретаря Общероссийской общественной организации «Ассоциация ревматологов России», главный внештатный специалист (Центральный федеральный округ), секретарь профильной комиссии, заведующая лабораторией медикосоциальных проблем ревматологии ФГБНУ «Научноисследовательский институт ревматологии им. В. А. Насоновой». • Коротаева Татьяна Викторовна-д. м.н., заведующая лабораторией спондилоартритов и спориатического артрита ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой». • Лапшина Светлана Анатольевна-к. м.н., доцент кафедры госпитальной терапии ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России. • Гайдукова Инна Зурабиевна-д. м.н., профессор кафедры терапии, ревматологии, экспертизы временной нетрудоспособности и качества медицинской помощи

arXiv (Cornell University), Jul 10, 2017

We consider optimal designs for general multinomial logistic models, which cover baseline-categor... more We consider optimal designs for general multinomial logistic models, which cover baseline-category, cumulative, adjacent-categories, and continuation-ratio logit models, with proportional odds, non-proportional odds, or partial proportional odds assumption. We derive the corresponding Fisher information matrices in three different forms to facilitate their calculations, determine the conditions for their positive definiteness, and search for optimal designs. We conclude that, unlike the designs for binary responses, a feasible design for a multinomial logistic model may contain less experimental settings than parameters, which is of practical significance. We also conclude that even for a minimally supported design, a uniform allocation, which is typically used in practice, is not optimal in general for a multinomial logistic model. We develop efficient algorithms for searching D-optimal designs. Using examples based on real experiments, we show that the efficiency of an experiment can be significantly improved if our designs are adopted.

$Research paper thumbnail of Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial$

Annals of the Rheumatic Diseases

ObjectivesTo evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patie... more ObjectivesTo evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs).MethodsAdults with active AS who met modified New York criteria and had an IR to one or two bDMARDs (tumour necrosis factor or interleukin-17 inhibitors) were randomised 1:1 to oral upadacitinib 15 mg once daily or placebo. The primary endpoint was Assessment of SpondyloArthritis international Society 40 (ASAS40) response at week 14. Sequentially tested secondary endpoints included Ankylosing Spondylitis Disease Activity score, Spondyloarthritis Research Consortium of Canada MRI spine inflammation score, total back pain, nocturnal back pain, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index and Maastricht Ankylosing Spondylitis Enthesitis Score. Results are reported from the 14-week double-blind treatment period...

RMD Open

ObjectivesTo assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib ... more ObjectivesTo assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in the ongoing long-term extension (LTE) of SELECT-COMPARE, a randomised controlled phase 3 trial of patients with active rheumatoid arthritis and inadequate response to methotrexate (MTX).MethodsPatients on stable background MTX were randomised 2:2:1 to upadacitinib 15 mg, placebo or adalimumab 40 mg. Patients with an insufficient response were switched by week 26 from placebo to upadacitinib, upadacitinib to adalimumab or adalimumab to upadacitinib. Patients who completed the 48-week double-blind period could enter an LTE for up to 10 years. Safety and efficacy results were analysed here through 3 years. Treatment-emergent adverse events (AEs) were summarised based on exposure to upadacitinib and adalimumab. Efficacy was analysed by original randomised groups (non-responder imputation), as well as separately by treatment sequence (as observed).ResultsRate...

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

The Lancet Rheumatology, 2022

Rheumatology and Therapy, 2021

Introduction: Upadacitinib is a Janus kinase inhibitor under investigation in patients with psori... more Introduction: Upadacitinib is a Janus kinase inhibitor under investigation in patients with psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in patients with PsA and an inadequate response or intolerance to biologic therapy. Methods: In the phase 3 SELECT-PsA 2 study, patients were randomized to 56 weeks of blinded treatment with oral upadacitinib 15 or 30 mg once daily, or placebo switched to upadacitinib 15 or 30 mg once daily at week 24. Efficacy endpoints included the proportion of patients achieving 20/50/70% improvement in American College of Rheumatology criteria (ACR20/50/70), 75/90/100% improvement in Psoriasis Area and Severity Index (PASI75/90/100),

BMC Complementary and Alternative Medicine, 2017

Question "Kneipp Therapy" (KT) is a form of Complementary and Integrative Medicine (CIM) that inc... more Question "Kneipp Therapy" (KT) is a form of Complementary and Integrative Medicine (CIM) that includes a combination of hydrotherapy, herbal medicine, mind-body medicine, physical activities and healthy nutrition. Several Nursing homes (NH) in Germany started to integrate KT in the routine care of residents. The aim of this study was to investigate if caring with KT has effects on caregivers. Methods We conducted a prospective, exploratory, two-armed cohort study to compare NH with (KT group) and without KT (but with routine health preventive interventions; control group) over 12 months. Each NH with KT was matched to a control. Outcomes for caregivers included the SF-12 Health Survey, the Work Ability Index (WAI) and the Copenhagen Psychosocial Questionnaire (COPSOQ). Results Altogether 111 caregivers were included from 7 NH (KT group, n = 48) respectively 6 NH (control group, n = 63). 95% of caregivers were female (43.4 ± 11.3 years, BMI 26.6 ± 5.3). At baseline, caregivers of the KT group showed better values for the COP-SOQ scales "feedback" (p = 0.043), "job satisfaction" (p < 0.001) and "burnout" (p = 0.008). After 6 months the control group was better in the COPSOQ scales "predictability of work" (p = 0.045) and after 12 months for "sense of community" (p = 0.047) and the physical component scale of the SF-12 (p = 0.039) compared to the KT group. Conclusions The study showed only minor differences between the caregivers of both groups. Caregivers´workability, quality of life and psychosocial burden at work seems to be less influenced by a CIM-oriented working-place approach. Trial Registration DRKS-ID: DRKS00005049 P246 Efficacy of adjuvant topical Juniperus excelsa versus cryotherapy alone in the treatment of cutaneous leishmaniasis: a double-blind randomized controlled clinical trial

Discussion about mechanism of harmful algal blooms breakout

HAB (harmful algal bloom) is a serious marine ecological disaster. Up to now there is no definite... more HAB (harmful algal bloom) is a serious marine ecological disaster. Up to now there is no definite conclusion about its mechanism of occurrence.The observation results show that the HAB breakout in the Xiangshan Bay was mainly caused by physical convergence ca pacity,and the breakout process had no direct relation to eutrophication. As a new idea it is thought that the process of the HAB break out is mainly a physical convergence or accumulation process in some areas. A hypothesis about dynamic mechanism of the HAB ap pearing in the area off the Changjiang Estuary is put forward according to hydrology and topography and the past work, and a breakthrough is expected to be made for doing further research.

The Annals of Statistics, 2020